Background-Measurement of B-type natriuretic peptide (BNP) concentration or its precursor (N-terminal fragment [NT-proBNP]) is recommended in patients with symptoms of left ventricular dysfunction and in other settings, but the relevance of these peptides to cardiovascular disease (CVD) in general populations or in patients with stable vascular disease is uncertain. Methods and Results-Data were collated from 40 long-term prospective studies involving a total of 87 474 participants and 10 625 incident CVD outcomes. In a comparison of individuals in the top third with those in the bottom third of baseline values of natriuretic peptides, the combined risk ratio (RR), adjusted for several conventional risk factors, was 2.82 (95% confidence interval [CI], 2.40 to 3.33) for CVD. Analysis of the 6 studies with at least 250 CVD outcomes (which should be less prone to selective reporting than are smaller studies) yielded an adjusted RR of 1.94 (95% CI, 1.57 to 2.39). RRs were broadly similar with BNP or NT-proBNP (RR, 2.89 [95% CI, 1.91 to 4.38] and 2.82 [95% CI, 2.35 to 3.38], respectively) and by different baseline vascular risk (RR, 2.68 [95% CI, 2.07 to 3.47] in approximately general populations; RR, 3.35 [95% CI, 2.38 to 4.72] in people with elevated vascular risk factors; RR, 2.60 [95% CI, 1.99 to 3
B -type natriuretic peptide (BNP) is a 32-amino acid polypeptide secreted by ventricular myocytes during periods of increased ventricular stretch and wall tension. This peptide is believed to play an important role in the regulation of blood pressure, blood volume, and sodium balance. On secretion, the BNP precursor is split into the biologically active peptide and the more stable N-terminal fragment (NT-proBNP). 1, 2 Measurement of circulating levels of BNP or NT-proBNP has been recommended in the diagnosis and prognosis of patients with symptoms of left ventricular dysfunction 3 and for stratification of risk in patients with acute coronary syndromes. 4, 5 Because in vitro studies have reported that natriuretic peptides are directly released from cardiomyocytes in response to myocardial ischemia, 6, 7 it has been proposed that their circulating levels are relevant to subsequent risk of cardiovascular diseases (CVDs) other than heart failure.
Clinical Perspective on p 2187
Although many prospective studies have investigated concentrations of natriuretic peptides in relation to the subsequent risk of CVD (eg, coronary heart disease [CHD] or stroke), most of them have not been systematically assessed. 8 -47 Two previous relevant reviews (in total involving 11 studies 48, 49 ) involved only about one sixth of the currently available data. Interpretation of the evidence has been complicated by studies that have involved different markers (ie, BNP, NT-proBNP, or both), populations with different base-line levels of CVD risk (eg, approximately general populations versus groups defined by elevated CVD risk factors versus patients with preexisting stable CVD), and/or different disease outcomes (eg, CHD or stroke). Furthermore, studies have reported apparently divergent findings on the extent to which assessment of concentrations of natriuretic peptides provides incremental predictive value beyond that provided by the use of conventional CVD risk factors alone.
We report an updated meta-analysis of findings from 40 long-term prospective studies of BNP and NT-proBNP involving a total of 87 474 individuals, including 10 625 incident CVD outcomes, in 3 distinct groups: participants from approximately general populations, people selected on the basis of elevated CVD risk factors, and patients with stable CVD at study entry.
Methods

Study Selection
We sought prospective studies that had been published before July 2009 and reported on associations of circulating BNP and/or NT-proBNP with CVD outcomes (defined as any fatal or nonfatal myocardial infarction [MI] , stroke, transient ischemic attack, or heart failure). Electronic searches of MEDLINE were supplemented by scanning reference lists of articles identified (including reviews and meta-analyses) and by correspondence with study investigators. The computer-based searches combined search terms related to the exposure (eg, natriuretic peptide, B-type natriuretic peptide, brain natriuretic peptide, N-terminal pro B-type natriuretic peptide, BNP, NT proBNP) and outcomes of interest (eg, cardiovascular, CHD, myocardial infarction, MI, cerebrovascular, stroke, transient ischemic attack, etc), without any language restriction ( Figure 1 ). Studies were eligible for inclusion if they had at least 1 year of follow-up and involved any of the following participants: approximately general populations (ie, participants not selected on the basis of preexisting disease at baseline), people selected on the basis of elevated CVD risk factors, or patients with stable CVD at study entry, defined as a diagnosis made at least 30 days before baseline of any of MI, angina, other CHD, stroke (including transient ischemic attack), or coronary surgery (including revascularization). Studies that involved patients with heart failure or with acute coronary syndromes at entry were excluded.
Data Extraction
Data on the following characteristics were independently extracted by 2 investigators who used standardized data extraction protocols and corresponded with study authors to obtain supplementary tabular data: study size; study population (defined as described above); sampling framework (defined as general population cohorts, hospital registers, or clinical trials); geographical location (defined as Europe, North America or Asia-Pacific); year of baseline survey; age range of participants at baseline; percentage of male participants; mean duration of follow-up; blood sample type (plasma or serum); storage temperature; natriuretic peptide assay methods; mean and SD of BNP and/or NT-proBNP; numbers of disease outcomes of interest; reported degree of adjustment for potential confounders (defined as ϩ when risk ratios [RRs] were adjusted for conventional CVD risk factors and as ϩϩ after further adjustment for serum creatinine, left ventricular ejection fraction, or C-reactive protein); and reported RRs for each outcome. Information was also sought on reported measures of CVD risk discrimination (such as area under the receiver-operator characteristics curve or C index), with and without inclusion of BNP or NT-proBNP. In instances of multiple publications, the most up-to-date or comprehensive information was used.
Statistical Analysis
Analyses involved only within-study comparisons (ie, cases and controls were directly compared only within each cohort) to limit potential biases. Principal analyses assessed associations of either BNP or NT-proBNP with CVD risk. Subsidiary analyses separately assessed associations with CHD (generally defined as MI or coronary death) and stroke (defined as ischemic, hemorrhagic, or unclassified stroke) because only a subset of studies reported on Di Angelantonio et al Natriuretic Peptides and Cardiovascular Risk these outcomes separately. To enable a consistent approach to analysis in this review, risk estimates for each study were transformed to involve comparisons between the top third and bottom third of the population's baseline distribution of natriuretic peptides values using methods previously described. 50 Briefly, log risk estimates were transformed assuming a normal distribution, with the comparison between top and bottom thirds being equivalent to 2.18 times the log RR for a 1-SD increase (or equivalently as 2.18/2.54 times the log RR for a comparison of extreme quarters). SEs of the log RRs were calculated using published confidence limits and were transformed in the same way. Hazard ratios and odds ratios were assumed to approximate the same measure of relative risk. Summary RRs were calculated by pooling the study-specific estimates using a random-effects model that included between-study heterogeneity (parallel anal-yses used fixed-effect models). When studies reported RRs with differing degrees of adjustment for other risk factors, the most adjusted estimate was used. Consistency of findings across studies was assessed by standard 2 tests and the I 2 statistic. 51 Heterogeneity was assessed by comparing results from studies grouped according to prespecified study-level characteristics with meta-regression. Evidence of publication bias was assessed with funnel plots, with the Egger test, 52 and by comparing pooled results from studies involving at least 250 cases with those from smaller studies. Findings in relation to risk discrimination metrics reported in different studies were displayed graphically, but combined analyses of these findings were not attempted owing to differences in the statistical metrics used, variables incorporated in risk prediction models, and source populations studied (see Discussion). All analyses were performed with Stata release 10 
Results
Forty relevant studies reporting on 87 474 individuals were identified, including 17 studies (involving a total of 41 878 individuals) providing supplementary or previously unreported data (the Table) . Twenty-three studies were based in Europe, 8 -28,46,47 5 in North America, 29 -33 1 in Australia and New Zealand, 34 and 7 in East Asia [35] [36] [37] [38] [39] [40] 45 (predominantly in Japan), and 4 were multinational. [41] [42] [43] [44] Thirty-six studies were prospective cohorts and 4 "nested" case-control studies; 14 studies recruited participants from population registers (such as general practitioners' lists or electoral rolls), and 26 were hospital based (of which 10 were clinical trials). Eleven studies recruited in approximately general populations (27 785 participants; 1271 CVD cases; average follow-up ranging from 2.0 to 12.8 years); 11 recruited individuals with elevated CVD risk factors (13 387 participants; 2040 CVD cases; average follow-up ranging from 1 to 15.5 years); and 18 recruited people with stable CVD at entry (46 302 participants; 7314 CVD cases; average follow-up ranging from 1.4 to 6.7 years). Among the 11 studies that recruited participants from approximately general populations, 5 excluded individuals with a history of CVD at baseline, and 6 reported a prevalence of CVD ranging from 5% to 20%. Thirty studies reported associations with NT-proBNP only, 7 with BNP only, and 3 with both natriuretic peptides. NT-proBNP and BNP levels varied substantially across available studies (NT-proBNP values ranged from 30 to 750 pg/mL; BNP values ranged from 9 to 142 pg/mL), with a tendency toward higher values in individuals with stable CVD compared with general populations. All 40 studies reported adjustment for at least several conventional vascular risk factors (ie, age, sex, smoking, history of diabetes mellitus, blood pressure, and lipids), including 33 studies that reported adjustment for conventional risk factors plus additional characteristics. Because published studies tended not to report separate RRs for vascular outcomes apart from CHD and stroke, it was not possible to disaggregate findings in relation to additional outcomes (eg, heart failure; see Discussion).
Associations With CVD Risk
During a weighted mean follow-up duration of approximately 5 years, a total of 10 625 incident CVD outcomes were recorded. In a comparison of individuals in the top third of baseline levels of either natriuretic peptide with those in the bottom third of the population, the RR for CVD, adjusted for at least several conventional risk factors, was 2.82 (95% confidence interval [CI], 2.40 to 3.33) or 2.24 (95% CI, 2.12 to 2.37) in fixed-effect analysis (Figure 2 and Figure I of the online-only Data Supplement). Although there was considerable heterogeneity among the 40 available studies (I 2 ϭ83%; 95% CI, 77 to 87), little of it was explained by study population, type of natriuretic peptide assayed, or whether the studies included heart failure in composite CVD outcomes ( Figure  3 ). Studies that involved at least 250 CVD outcomes tended to report somewhat lower RRs than smaller studies (Pϭ0.011; Figure 3 ). Funnel plots suggested more extreme findings in smaller studies (Egger test, Pϭ0.002; Figure II of the online-only Data Supplement). Analysis of the 6 studies with at least 250 CVD outcomes (which should be less prone to selective reporting than are smaller studies) yielded an adjusted RR of 1.94 (95% CI, 1.57 to 2.39). In studies that reported on separate CVD outcomes, the adjusted RR for CHD was 2.03 (95% CI, 1.54 to 2.66) or 2.25 (95% CI, 2.07 to 2.44) in fixed-effect analysis (4301 cases of MI or CHD death; 56 335 participants; 19 studies: Figure 2 and Figure III of Figure 2 and Figure IV of the online-only Data Supplement). There was considerable heterogeneity among studies of CHD (I 2 ϭ88%; 95% CI, 83 to 92) and stroke (I 2 ϭ55%; 95% CI, 15 to 76), but again, little of it was explained by the study characteristics recorded.
CVD Risk Discrimination Models
Fourteen studies reported on changes in measures of risk discrimination upon the addition of either BNP or NT- Figure 3 . Relative risks for CVD in individuals in the top vs bottom third of baseline BNP or NT-proBNP according to different studylevel characteristics. PϾ0.05 from meta-regression analyses on each of the covariates unless otherwise specified. ¶Four multicenter studies were excluded. *Pϭ0.011 from meta-regression analysis. ‡Levels of adjustment in multivariate models. ϩAdjusted for conventional cardiovascular factors (ie, age, sex, smoking, history of diabetes mellitus, blood pressure [and/or history of hypertension], total cholesterol [or non-high-density lipoprotein cholesterol], and high-density lipoprotein cholesterol). ϩϩFurther adjusted for other potential risk factors (ie, further adjustment for serum creatinine, left ventricular ejection fraction, or C-reactive protein). †Five studies did not specify sample type. ranging from 0.01 to 0.1 (Figure 4) . There was a possible tendency toward smaller increments in risk discrimination in larger studies and studies in approximately generally populations, although this could not be formally assessed owing to lack of access to individual participant data.
Discussion
The present review of Ͼ80 000 participants and Ͼ10 000 patients with vascular disease from 40 long-term prospective studies has assessed the strength and consistency of associations between levels of BNP and/or NT-proBNP with subsequent risk of CVD. Overall, there was an almost 3-fold increase in risk of CVD in people in the top third of baseline natriuretic peptide values compared with those in the bottom third, even after reported adjustment for several conventional risk factors. In studies that were potentially less prone to publication bias, however, the relative risk for CVD was only Ϸ2-fold. The association was similarly strong in essentially general populations and in people with prevalent CVD, in studies with both shorter and longer-term average follow-up, and apparently irrespective of inclusion of heart failure.
Furthermore, although BNP and NT-proBNP have different plasma half-lives (Ϸ20 minutes versus Ϸ90 minutes, respectively) and differ in range of circulating values, 2 present data suggest that a given proportional increment in each marker is similarly associated with increased CVD risk.
On the basis of indirect comparisons with previous systematic reviews of several established and emerging risk factors, the magnitude of the CVD risk with natriuretic peptide concentration appears to be at least as strong as those with total cholesterol, fibrinogen, or C-reactive protein. [53] [54] [55] But, despite the strong associations with CVD risk observed in the present review, assessment of BNP or NT-proBNP in addition to measurement of conventional CVD risk factors (and other characteristics) yielded apparently modest incremental improvement in risk discrimination for subsequent CVD.
In recent years, there has been a progressive extension of indications for measurement of natriuretic peptides in the diagnosis and prediction of CVD. Assay of BNP or NT-proBNP has been recommended for incorporation into clinical practice for the diagnosis of suspected acute or chronic heart failure (measurement of these peptides can rule out heart failure with a very high degree of accuracy), the prognosis of patients with heart failure or asymptomatic left ventricular dysfunction, and determination of treatment for patients with heart failure and monitoring of treatment effects. 3, 56 Furthermore, because BNP is released after cardiac ischemia, measurement of the peptide has also been proposed to be a useful biomarker for risk stratification in patients with acute coronary syndrome, 4 although this has not gained widespread use because its role in defining therapeutic strategies is still unclear. 5 It has been suggested that further extension of natriuretic peptides measurements in clinical practice to individuals without significant heart failure may help to identify either those with a high burden of coronary disease or individuals prone to episodes of subclinical plaque rupture. Natriuretic peptide levels have been reported to increase progressively with increasing numbers of diseased coronary arteries, 57, 58 possibly reflecting increased cardiac expression and release of natriuretic peptides during myocardial ischemia. 6 Studies of percutaneous coronary angiography also demonstrate that circulating natriuretic peptide values increase transiently during balloon inflation and fall after resolution of ischemia. 59, 60 However, studies in the present review reporting on measures of risk prediction (as distinct from those reporting RRs) included only one fourth of the CVD cases in the available studies. Moreover, only 2 studies 28,46 reported on reclassification measures.
Although the present study involves Ͼ6 times as much information as in previous reviews, 48, 49 this meta-analysis has been limited by the moderate amount of available data from certain relevant populations. For example, there are a total of only Ϸ2000 incident CVD outcomes in studies of patients with elevated CVD risk factors at baseline and only Ϸ1000 incident CVD outcomes in studies of general populations. Hence, much more data are needed from low-and intermediate-risk populations to allow more confident extension of the present data to primary prevention settings (studies in such populations should also help to minimize potential reverse association biases related to preexisting disease or medication use). Whereas the present review is based on published findings (supplemented by limited tabular data provided by several investigators), more detailed combination of data on the basis of individual participant records would enable (1) more specific assessment of CHD and stroke (avoiding potential exaggeration resulting from inclusion of heart failure outcomes in composite definitions of CVD), (2) a more consistent approach to adjustment for potential confounding factors, (3) direct comparisons of the magnitude of risk associations with natriuretic peptides and conventional risk factors, (4) characterization of the shape of any dose-response relationships, and (5) a more consistent and comprehensive approach to the assessment of predictive accuracy. 28 Moreover, because the present review found evidence of more striking findings in smaller studies and only 5 of the included studies involved at least 250 CVD cases, there is a need for fresh data on natriuretic peptides from much larger individual studies. The potential for publication bias should also be reduced by pooled analyses of data from predefined consortia of studies. Serial assays are needed to assess within-person variability in natriuretic peptide values over time (ie, "regression dilution") 61 because published RRs may have been prone to underestimation because none of the available studies has corrected for this variability.
Conclusions
Available prospective studies indicate strong associations between the circulating concentration of natriuretic peptides and CVD risk under a range of different circumstances. However, because the majority of available studies have been conducted in people with stable vascular disease, further and more detailed investigation is warranted, particularly in general population settings, to clarify whether measurement of these markers can usefully enhance CVD stratification beyond established predictors already in clinical use.
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